BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35953764)

  • 1. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
    Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
    Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
    Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
    Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
    Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
    Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
    Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
    Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
    Roderwieser A; Sand F; Walter E; Fischer J; Gecht J; Bartenhagen C; Ackermann S; Otte F; Welte A; Kahlert Y; Lieberz D; Hertwig F; Reinhardt HC; Simon T; Peifer M; Ortmann M; Büttner R; Hero B; O'Sullivan RJ; Berthold F; Fischer M
    JCO Precis Oncol; 2019 Dec; 3():1-20. PubMed ID: 35100718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 11. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
    Mender I; LaRanger R; Luitel K; Peyton M; Girard L; Lai TP; Batten K; Cornelius C; Dalvi MP; Ramirez M; Du W; Wu LF; Altschuler SJ; Brekken R; Martinez ED; Minna JD; Wright WE; Shay JW
    Neoplasia; 2018 Aug; 20(8):826-837. PubMed ID: 30015158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
    Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
    Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
    Yu Y; Zhao Y; Fan Y; Chen Z; Li H; Lu J; Guo K; Woodfield SE; Vasudevan SA; Yang J; Nuchtern JG
    Mol Cancer Ther; 2019 Jun; 18(6):1045-1056. PubMed ID: 30962318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
    Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
    Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
    Taylor JS; Yavuz B; Zeki J; Wood L; Ikegaki N; Coburn J; Harrington K; Shimada H; Kaplan DL; Chiu B
    Surgery; 2020 Jun; 167(6):969-977. PubMed ID: 32122657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.